

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7852202

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HUIEDIT THERAPEUTICS CO., LTD.	01/27/2023
RECEIVING PARTY DATA	
Name:	HUIGENE THERAPEUTICS CO., LTD.
Street Address:	ROOM 1002, BUILDING #7-1, NO. 160 BASHENG ROAD
Internal Address:	PUDONG DISTRICT
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201203
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17819795
PCT Number:	CN2022089074
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508135736
Email:	earreola@mofo.com
Correspondent Name:	JIAN XIAO
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	755 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	23346-20001.00
NAME OF SUBMITTER:	JIAN XIAO
SIGNATURE:	/Jian Xiao/
DATE SIGNED:	03/17/2023
Total Attachments: 3	
source=23346-20001.00 Assignment of HuiEdit to HuiGene#page1.tif	
source=23346-20001.00 Assignment of HuiEdit to HuiGene#page2.tif	
source=23346-20001.00 Assignment of HuiEdit to HuiGene#page3.tif	

ASSIGNMENT

This assignment is by:

Assignor: HuiEdit Therapeutics Co., Ltd.
 Address: Floor 6, Unit 8-2, No. 160, Basheng Road, Pilot Free Trade Zone
 Shanghai, P.R. China 200131
 A juristic entity duly organized under and pursuant to the laws of: P.R. China

(referred to in this Assignment as "Assignor"), whose mailing address information is listed above.

This Assignment is to:

Assignee: HuiGene Therapeutics Co., Ltd.
 Address: Room 1002, Building #7-1, No. 160 Basheng Road, Pudong District, Shanghai, P.R.
 China, 201203
 A juristic entity duly organized under and pursuant to the laws of: P.R. China

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions set forth in:

Internal Ref.	Agency Ref.	Invention title	Office	Application No.	Filing Date
HEP001CN	CID210098/23346-20001.40	NOVEL CRISPR-CAS12I SYSTEMS	CNIPA	202111290670.8	2021/11/2
HEP001US	23346-20001.00	NOVEL CRISPR-CAS12I SYSTEMS	USPTO	17/819,795	2022/8/15
HEP001P1	CID210099/23346-20001.42	NOVEL CRISPR-CAS12I SYSTEMS	CNIPA	202111289092.6	2021/11/2
HEP001P2	CID220003/23346-20001.41	NOVEL CRISPR-CAS12I SYSTEMS	CNIPA	202210081981.1	2022/1/24
HEP001P3	CIE220038PCT/23346-20001.44	NOVEL CRISPR-CAS12I SYSTEMS	WIPO	PCT/CN2022/089074	2022/4/25

(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to, Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, Patent Cooperation Treaty (PCT) application, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in P.R. China, the United States of America, and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any

and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said PCT application, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said PCT application, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignees, its successors, legal representatives and assigns, or to a predecessor interest of Assignees, Assignor's entire right, title and interest in and to said inventions and said PCT application.

3. Assignor shall promptly sign, execute and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said PCT application; (b) any and all non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modification to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the patent office officials in P.R. China, the United States, and all foreign countries or jurisdictions to issue the above mentioned letters patent or patents and any reissue, reexamination, review, modifications, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent or patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys of the applicable country appointed and authorized by Assignee the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of China National Intellectual Property Administration, the United States Patent and Trademark office, or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the dates opposite the undersigned names.

ASSIGNOR:

Date: Jan. 27, 2023 Signature: / ZHOU Yingsi /
Name: ZHOU Yingsi
Title: Legal Representative
Company: HuiEdit Therapeutics Co., Ltd.

ASSIGNEE:

Date: Jan. 27, 2023 Signature: / YAO Xuan /
Name: YAO Xuan
Title: CEO
Company: HuiGene Therapeutics Co., Ltd.